Deep knowledge on 
 small-molecule drugs and 
 the 110,000 global patents 
 covering them 

Free Patent Expiration Alerts


Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Ritonavir - Generic Drug Details

« Back to Dashboard
Ritonavir is the generic ingredient in two branded drugs marketed by Abbvie, Roxane, and Abbott, and is included in five NDAs. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has seventy patent family members in thirty-one countries.

There are twenty-one drug master file entries for ritonavir. Three suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for Generic Name: ritonavir

Tradenames:2
Patents:11
Applicants:3
NDAs:5
Drug Master File Entries: see list21
Suppliers / Packaging: see list3
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Tentative approvals for RITONAVIR

Applicant Application No. Form Dosage
<disabled><disabled>TABLET;ORAL100MG
<disabled><disabled>TABLET;ORAL100MG
<disabled><disabled>TABLET; ORAL25MG

Clinical Trials for: ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999RXYes6,037,157*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996RXYes6,703,403*PED<disabled>Y<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 1999RXYes7,141,593*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ritonavir

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 19965,886,036*PED<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 19995,541,206*PED<disabled>
Abbvie
NORVIR
ritonavir
CAPSULE;ORAL020945-001Jun 29, 19995,674,882*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: ritonavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,025,899Solid pharmaceutical dosage form<disabled in preview>
6,458,818 Pharmaceutical composition<disabled in preview>
8,674,112Polymorph of a pharmaceutical<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ritonavir

Country Document Number Estimated Expiration
Georgia, Republic ofP20105083<disabled in preview>
World Intellectual Property Organization (WIPO)2006091529<disabled in preview>
Australia2006216856<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RITONAVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/044United Kingdom<disabled>PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
00060Netherlands<disabled>PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320
0674513Switzerland<disabled>PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Connect with Social Media:

`abc